0.75  -0.02 (-2.61%)		04-20 16:00
Open: 0.756 High: 0.79 Volume: 17,319		Pre. Close: 0.7701 Low: 0.7473 Market Cap: 41(M)

Short term
Mid term
Targets	6-month :	0.9	1-year :	0.94
Resists	First :	0.77	Second :	0.8
Pivot price	0.75
Supports	First :	0.72	Second :	0.59
MAs	MA(5) :	0.75	MA(20) :	0.75
	MA(100) :	0.96	MA(250) :	1.29
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	60.5	D(3) :	58.6
RSI	RSI(14): 43.3
52-week	High :	1.76	Low :	0.68

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INCR ] has closed above bottom band by 34.4%. Bollinger Bands are 77.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.79 - 0.8	0.8 - 0.8
Low:	0.74 - 0.74	0.74 - 0.75
Close:	0.74 - 0.75	0.75 - 0.76

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Mon, 20 Apr 2026
Intercure (INCR) director discloses shares and stock options - Stock Titan

Mon, 20 Apr 2026
Intercure (INCR) director reports 15,000 share options at $3.10 strike - Stock Titan

Mon, 20 Apr 2026
Intercure (INCR) CEO details major share, warrant and option holdings - Stock Titan

Thu, 16 Apr 2026
Intercure (INCR) director Gideon Hirschfeld reports existing stock option grants - Stock Titan

Tue, 03 Mar 2026
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement - GlobeNewswire

Tue, 03 Mar 2026
InterCure Ltd. Receives Nasdaq Compliance Notice Due to Bid Price Deficiency, Plans to Regain Compliance - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	55 (M)
Shares Float	39 (M)
Held by Insiders	26 (%)
Held by Institutions	1.3 (%)
Shares Short	20 (K)
Shares Short P.Month	21 (K)

EPS	-0.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.59
Profit Margin	-29.2 %
Operating Margin	0 %
Return on Assets (ttm)	-7.8 %
Return on Equity (ttm)	-16.7 %
Qtrly Rev. Growth	3.4 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.48
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-1.48
PEG Ratio	0
Price to Book value	0.09
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.